Tucatinib: all 51 studies that test it

Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• Tucatinib Continuation StudyNot yet recruitingNCT07768358Phase 4
• ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingNCT07318389Early Phase 1
• Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast CancerRecruitingNCT07193394Phase 2
• The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingNCT06439693Phase 2
• Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 StudyRecruitingNCT06162559Phase 1
• Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell CancerNot yet recruitingNCT06067776Phase 1
• Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility StudyRecruitingNCT06016387Phase 2
• PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingNCT05868226Phase 1/2
• Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseaseRecruitingNCT05800275Phase 2
• Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerRecruitingNCT05748834Phase 2
• A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)RecruitingNCT05673928Phase 2
• A Study of Tucatinib and Trastuzumab in People With Rectal CancerRecruitingNCT05672524Phase 2
• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerRecruitingNCT05253651Phase 3
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
• A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerActive, not recruitingNCT05132582Phase 3Results posted
• A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)Active, not recruitingNCT04721977Phase 2Results posted
• A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedNCT04632992Phase 2Results posted
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive, not recruitingNCT04579380Phase 2Results posted
• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerCompletedNCT04539938Phase 2Results posted
• Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal CancerCompletedNCT04499924Phase 2/3Results posted
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerActive, not recruitingNCT03975647Phase 3Results posted
• Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMDTerminatedNCT03501979Phase 2Results posted
• Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast CancerCompletedNCT03054363Phase 1/2Results posted
• A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast CancerCompletedNCT02614794Phase 2Results posted
• A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the BrainActive, not recruitingNCT05892068Phase 2
• Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast CancerTerminatedNCT05583110Phase 2
• Tucatinib+Trastuzumab+Eribulin in HER2+ MBCActive, not recruitingNCT05458674Phase 2
• Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)Active, not recruitingNCT05382364Phase 1
• Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T StudyWithdrawnNCT05356897Phase 2
• Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of TucatinibActive, not recruitingNCT05323955Phase 2
• Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerActive, not recruitingNCT05319873Phase 1/2
• Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.Active, not recruitingNCT05230810Phase 1/2
• Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast CancerWithdrawnNCT05227131Phase 2
• Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer PatientsSuspendedNCT05062889Phase 2
• Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast CancerActive, not recruitingNCT05041842Phase 2
• Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.WithdrawnNCT04896320Phase 1/2
• Tucatinib Together With Pembrolizumab and TrastuzumabTerminatedNCT04789096Phase 2
• TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain MetastasesWithdrawnNCT04512261Phase 1/2
• T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialActive, not recruitingNCT04457596Phase 3
• A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian SubjectsCompletedNCT03914755Phase 1
• Tucatinib + Abemaciclib + Herceptin for HER2+ MBCWithdrawnNCT03846583Phase 1
• A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on MetforminCompletedNCT03826602Phase 1
• Effects of Tucatinib on Cardiac Repolarization in Healthy ParticipantsCompletedNCT03777761Phase 1
• A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy ParticipantsCompletedNCT03758339Phase 1
• A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of TucatinibCompletedNCT03723395Phase 1
• A Safety Study of Tucatinib in Healthy and Hepatically-Impaired SubjectsCompletedNCT03722823Phase 1
• A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast CancerCompletedNCT01983501Phase 1
• ARRY-380 + Trastuzuamab for Breast w/ Brain MetsCompletedNCT01921335Phase 1
• A Study of ARRY-380 in Patients With Advanced HER2+ CancerCompletedNCT00650572Phase 1

← Tucatinib overview